1. dwaysche
2. kirkskraft
3. lieselloveszach
4. 4tokoma4tokoma
5. nlanas2sk051p
1.lieselloveszach 06/28/2018
Cantor Fitzgerald reiterates Buy rating, $42 PT
2.4tokoma4tokoma 02/22/2018
We should be over 40 by now
3.lieselloveszach 03/06/2018
Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
4.lieselloveszach 10/23/2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
5.kirkskraft 02/22/2018
Nice boost
6.dwaysche 02/21/2018
Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
7.4tokoma4tokoma 01/09/2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
8.lieselloveszach 06/08/2018
Piper Jaffray sets PT at $48
9.kirkskraft 02/22/2018
Will be in the 40 range soon.
10.4tokoma4tokoma 01/10/2019
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW